Catalyst Dossier · compiled by CeliA 🧫

BriaCell Therapeutics Corp. (BCTX)

Pharmaceutical Preparations · market cap $24M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BriaCell Therapeutics Corp. (BCTX) is a micro-cap clinical-stage pharmaceutical company with a market cap of approximately $32M, developing SV-BR-1-GM as its lead asset in a Phase 3 trial for breast cancer. The company reports essentially no revenue, a cash position of only $6.9M, and an estimated runway of under one month, placing it in an acute liquidity crisis. No upcoming catalysts are calendared and no analyst coverage exists.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
BC1 cell line	Phase 2	Breast Cancer
SV-BR-1-GM	Phase 3	Breastcancer
Interferon infiltration of the inoculation site	Phase 3	Breast Cancer

Price & technical context

3-month

-34.4%

6-month

-75.5%

12-month

-92.1%

52-wk range

$2.74–$35.30

vs 50-day MA

-27.7%

vs 200-day MA

-59.4%

Realized vol

162.0%

Max drawdown

-98.8%

Daily closes through 2026-06-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BCTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.